Flexible Stenting Solutions (FSS) has enrolled the first patients in two trials of its FlexStent, a femoropopliteal stent and delivery system.
The two trials are the Japan FlexStent clinical trial and the US FlexStent OPEN trial in Belgium.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The prospective, multicentre and randomised Japan FlexStent clinical trial will enrol 100 patients and compare the FlexStent with balloon angioplasty.
The company hopes that the system will improve patient care in the high growth peripheral vascular segment.
